Please ensure Javascript is enabled for purposes of website accessibility

Sanofi and Denali Halt Clinical Trials of Alzheimer Drug

By Taylor Carmichael – Updated Jun 10, 2020 at 2:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The companies are shifting their joint efforts from DNL747 to DNL788, which has stronger preclinical data.

On Tuesday, Sanofi (SNY 2.37%) and Denali Therapeutics (DNLI 3.77%) announced they were halting clinical trials for one of Denali's drugs, DNL747. While the drug candidate proved to be safe at the dosage tested in the phase 1 trial, the results suggested that the molecule might not help people with Alzheimer's or ALS (Lou Gehrig's disease) unless the dosage was increased. And such an increase might cause safety issues in humans.

Instead, the two companies are going forward with the "back-up compound," DNL788, as that molecule had superior results in animal testing. "[W]e have decided to pause clinical studies with DNL747 and focus our efforts on accelerating development of DNL788, which we believe has superior drug properties and a more rapid path toward proof-of-concept clinical studies in patients in multiple neurological indications," said Denali CEO Ryan Watts.

march for ALS

Image source: Getty Images

Back in 2018, Sanofi and Denali inked a collaboration deal; the European pharmaceutical giant paid $125 million to Denali for partial rights in a pair of RIPK1 inhibitors, DNL747 and DNL758. These two molecules inhibit the receptor-interacting protein kinase-1, which is thought to play a role in many diseases, including Alzheimer's, ALS, and multiple sclerosis. (DNL758 is being tested in peripheral inflammatory disease and rheumatoid arthritis).

While the halting of the DNL747 lead molecule is disappointing, the market's reaction so far has been rather muted. In early trading on Wednesday, Denali's stock is up slightly. Presumably, this is because the two companies still have a strong candidate molecule, DNL788, and their collaboration remains intact.

Indeed, sometimes substitutes are amazing. Maybe one day we'll refer to DNL788 as "Lou Gehrig" and the halted candidate DNL747 will be "Wally Pipp."   

Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$40.12 (2.37%) $0.93
Denali Therapeutics Inc. Stock Quote
Denali Therapeutics Inc.
DNLI
$32.21 (3.77%) $1.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.